Agenus vs Compugen
AGEN and CGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGEN and CGEN compare
Compugen grew revenue faster over the last twelve months (161% versus 30.5% for Agenus).
Compugen scores higher on the StockData Score (12 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGEN | CGEN |
|---|---|---|
| Size and price | ||
| Market cap | $283M | – |
| Share price | $6.29 | $2.02 |
| Change, 1 year | 45.3% | 23.2% |
| Change, 5 years | −90.3% | −55.5% |
| Beta (5Y) | 1.01 | 1.55 |
| Employees | 81 | 2 |
| StockData Score | ||
| Total score | 3 | 12 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.1× | – |
| EV/EBITDA | 7.0× | – |
| FCF yield | −34.8% | – |
| Growth | ||
| Revenue growth (TTM) | 30.5% | 161% (better) |
| Revenue growth, 5Y average | 5.3% | 105% (better) |
| Profitability | ||
| Gross margin | 99.5% (better) | 87.3% |
| Operating margin | 27.3% | 43.1% (better) |
| Net margin | – | 48.6% |
| FCF margin | −74.2% | 43.1% (better) |
| Return on equity | – | 50.9% |
| Return on invested capital | – | 117% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 0.28 | – |
| Interest coverage | 0.6× | – |
| Current ratio | 0.34 | 5.72 (better) |
| Altman Z-score | −16.54 | – |
| Piotroski F-score | – | 7 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 31.7% | – |
| Held by insiders | 6.6% | 0.43% |
| Insider net buying, 12 months | – | −$126K |
| Short interest, % of float | 18.1% | 2.7% |
Go deeper
- AGEN stock overview
- AGEN income statement
- AGEN valuation and score
- CGEN stock overview
- CGEN income statement
- CGEN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.